#Corticosteroids

[clatterbane]

Me, every time I eat a full meal lately. Thanks to the steroids they have me on for my throat. This isn't even the worst example recently, since I have been hesitating less to really hit the insulin hard.

(This is after bumping the long-acting background insulin up quite a bit, and making sure I wait long enough for the numbers to start heading down after taking the Novorapid before I actually start eating.)

I told the gastro endoscopy people who prescribed this shit that it was really screwing with my blood sugar when I had to go in the other day. The guy just shrugged, but of course he's not living with any of this. Hopefully they will not continue this garbage indefinitely. It's getting hard to deal with.

Tonight, I preemptively dosed about double the insulin that I normally would for the same supper. Then I may have slightly overdone the extra correction dose that I reached for after it hit 11/200 with a red arrow still pointing straight up.

So yeah, I may need to grab a little something else before it crashes too hard from that. This is all trial and error. That wasn't even a particularly big bowl of food, and I won't be that sorry to grab a snack.

I really do not want or need to go lower carb, but I may need to in another way for a while just to cut back on these crazy steroid spikes. As it is, I have purposely not been eating as much as usual in general, which is probably even less helpful with ED Jerkbrain always lurking around and waiting for a chance.

Trying pretty hard to just consider the numbers as useful data points. But, this can be harder to keep in mind when you have gotten blamed and browbeaten enough over the years over them running high due to, erm, misdiagnosis and treatment that did more harm than good. I do have slightly more control over things now, but not by very much because Steroid Chaos. Which is well known to do this shit.

ETA: And yes, now endocrinology is getting all the CGM data. Which makes me more nervous with the numbers looking worse. Nobody there has wanted to act like a complete asshole so far, at least. I know I don't have to take any unwarranted shit onboard if they did decide to start up with that, but I am still not particularly happy about every single "bad" reading being open to scrutiny these days.

[viscardiac]

Yall i haaaaaate being on corticosteroids this shit makes me very hungry and at the same time forever sugar crashed and nauseous. I don't need more sugar, it's high! But it makes me want it and feel honger

[blatterpussbunnyfromhell]

prednisolone my beloved <3

[netraeyehospital]

Netra Eye Hospital – 6 Common Causes of Glaucoma

At Netra Eye Hospital, we specialize in the diagnosis and treatment of various eye conditions, including glaucoma. Glaucoma is a serious eye condition that can lead to vision loss if left untreated. Here are 6 common causes of glaucoma:

Medical Conditions: Certain systemic diseases like diabetes, high blood pressure, and heart conditions can increase the risk of glaucoma.

Abnormalities in the Eye: Irregularities in the eye's anatomy can cause glaucoma by obstructing fluid drainage within the eye.

Optic Nerve Damage: Damage to the optic nerve, often caused by high intraocular pressure, can result in glaucoma.

Other Eye Conditions: Eye conditions such as cataracts and eye infections may contribute to the development of glaucoma.

Prolonged Use of Corticosteroids: Long-term use of corticosteroids, particularly in eye drops, can increase the risk of developing glaucoma.

Increased Intraocular Pressure: Elevated pressure inside the eye is the most significant risk factor for glaucoma and can damage the optic nerve over time.

If you are experiencing any symptoms or have a family history of glaucoma, it’s essential to get regular eye check-ups. Book an appointment with us today for a comprehensive eye examination.

Contact Information:

Phone: +91-9646624864 / 0172-4785252 Website: www.netraeyehospital.com Address: SCO-404, Sector 20 Rd, Sector 20, Panchkula, Haryana, 134116 Your eye health is our priority. Visit Netra Eye Hospital for expert care and treatment.

[creativeera]

IoT and Virtual Hospital Industry: Global IoT Enabling Next Generation Virtual Hospital

The healthcare industry is embracing new digital technologies at a rapid pace to improve patient outcomes and transform the delivery of care. Internet of Things (IoT) powered solutions are connecting medical devices, integrating telehealth capabilities, and enabling new care models like virtual hospitals that remove geographic barriers. By 2023, IoT healthcare spending is projected to reach $217 billion globally as innovations reshape every aspect of the patient experience from diagnosis to long-term wellness. Connecting Medical Devices with IoT and Virtual Hospital Industry At the core of Global IoT and Virtual Hospital is their ability to remotely monitor patients anytime from anywhere. This relies on medical devices being networked and sensors wirelessly transmitting vital sign data in real-time to the cloud for analysis. IoT is enabling a wide range of devices from blood pressure cuffs and glucose monitors to EKG and pulse oximetry equipment to seamlessly integrate with electronic health records systems. Doctors can easily access streams of patient data via mobile or web applications to track recovery, identify issues early, and proactively adjust care plans as needed from a distance. For example, IoT enabled ventilators allow respiratory therapists to monitor lung function remotely for COPD and asthma patients at high risk of exacerbations. Delivering Telehealth at Scale One of the key benefits of IoT powered virtual hospitals is their ability to provide telehealth services to many more patients across broader geographies. Instead of relying on in-person clinic or hospital visits which can be time-consuming and costly for those in remote areas, IoT infrastructure facilitates real-time video consultations, remote patient monitoring, and live specialist evaluations anytime via mobile or web. This improves access to quality care for underserved communities worldwide. Leading health systems are implementing IoT ecosystems that seamlessly integrate telehealth capabilities like virtual check-ins, remote patient monitoring, and medical device data straight into their telemedicine portals and workflows. The Doximity platform, for example, connects over 560,000 physicians virtually to deliver telehealth at an unmatched scale. Transforming Care Delivery Models IoT is revolutionizing traditional care delivery models through new virtual hospital concepts that reimagine where and how healthcare is provided. Remote patient monitoring is shifting many services like post-acute care, senior care, and chronic disease management to the home. U.S. virtual health provider BestDOT utilizes an IoT platform to enable full service hospitals without physical infrastructure by leveraging connected medical equipment, EHR integrations, telehealth carts and a care coordination system available anywhere. Their virtual hospitals can stand up pop-up clinics or replace facilities damaged by natural disasters, improving both capacity and disaster response. Get more insights on Global IoT and Virtual Hospital

About Author:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)

[cassandrawallac]

Understanding the Difference Between Antihistamines and Corticosteroids

When treating allergic reactions or inflammations, two types of medicines are most commonly known as antihistamines and corticosteroids although they function differently. Antihistamines act on histamine secretion to counter common allergy effects such as sneezing, congestion as well as itchiness. There are two kinds H1 for allergy conditions and H2 for gastrointestinal conditions. Corticosteroids, on the other hand are potent anti-inflammatory agents of the glucocorticoids and they belong to the family of steroid hormones. They are commonly used in management of conditions such as asthma, arthritis and inflammatory bowel disease. In contrast to antihistamines, corticosteroids inhibit the activity of the immune system and decrease irritation at its root.

Read more: What sets antihistamines apart from corticosteroids

[drforambhuta]

Osteoarthritis (OA):

Described as degenerative joint disease, osteoarthritis stands as the most prevalent type of arthritis. It arises when the protective cartilage guarding the ends of bones deteriorates over time, resulting in discomfort, rigidity, and inflammation in the impacted joints. Although it can affect any joint, osteoarthritis commonly targets the knees, hips, hands, and spine.

Etiology:

• Aging: The likelihood of osteoarthritis escalates with age due to the accumulation of joint wear and tear over time.

• Joint trauma: Previous injuries to joints, such as fractures or ligament tears, can predispose individuals to osteoarthritis.

• Obesity: Excess body weight imposes additional stress on weight-bearing joints, fostering the onset and progression of osteoarthritis.

Symptoms:

• Pain: Persistent joint pain intensifying with activity and subsiding with rest.

• Rigidity: Joint stiffness, notably in the morning or following periods of inactivity.

• Inflammation: Noticeable swelling and tenderness around affected joints.

Treatment:

• Medications: Over-the-counter pain relievers like acetaminophen or nonsteroidal anti-inflammatory drugs (NSAIDs) can mitigate pain and inflammation.

• Physical therapy: Specific exercises and stretches aim to enhance joint flexibility, strength, and range of motion.

• Weight management: Maintaining a healthy weight diminishes stress on weight-bearing joints and decelerates osteoarthritis progression.

• Injections: Corticosteroid or hyaluronic acid injections might offer temporary symptom relief.

Rheumatoid Arthritis (RA):

Rheumatoid arthritis constitutes an autoimmune ailment characterized by synovium inflammation, the joint lining. This persistent inflammatory condition primarily affects the small joints of the hands and feet but can also involve other bodily organs and systems. Unlike osteoarthritis, which stems mainly from wear and tear, rheumatoid arthritis arises from the immune system mistakenly attacking the body's own tissues.

Etiology:

• Genetic predisposition: Specific genetic factors heighten rheumatoid arthritis risk, though environmental triggers are also deemed influential.

• Environmental factors: Exposure to certain elements like smoking or infections may incite rheumatoid arthritis onset in genetically susceptible individuals.

• Immune system malfunction: In rheumatoid arthritis, the immune system erroneously assaults the synovium, culminating in chronic inflammation and joint deterioration.

Symptoms:

• Joint pain and swelling: Symmetrical joint involvement, with pain, swelling, and stiffness affecting multiple joints concurrently.

• Fatigue: Persistent fatigue and malaise, often accompanied by a mild fever.

• Morning stiffness: Prolonged morning stiffness persisting for over an hour upon awakening.

• Rheumatoid nodules: Firm subcutaneous lumps, typically around elbows and fingers.

Treatment:

• Disease-modifying antirheumatic drugs (DMARDs): Medications such as methotrexate, hydroxychloroquine, and sulfasalazine help suppress the immune system and curb inflammation.

• Biologic agents: Biologic DMARDs like tumor necrosis factor (TNF) inhibitors or interleukin-6 (IL-6) inhibitors target specific immune system components involved in rheumatoid arthritis.

• Corticosteroids: Short-term corticosteroid use aids in alleviating acute symptoms such as pain and inflammation.

• Physical therapy: Exercises aimed at improving joint mobility, strength, and function, alongside splints or orthotics for joint support.

You can find some very good hospitals in India that offer health checkup packages to undergo a regular full body health checkup, which can be beneficial in the early diagnosis and treatment of conditions like arthritis.

[drsurbhikapadia]

Thyroid Eye Disease: Expert Treatment and Care by Dr. Surbhi Kapadia

Thyroid Eye Disease (TED) is a condition that not only affects ocular health but also significantly impacts the quality of life. In Vadodara, Dr. Surbhi Kapadia stands as a beacon of hope for those suffering from TED, offering advanced treatment options and comprehensive care.

Advanced Treatment Options for Thyroid Eye Disease

Dr. Kapadia employs a multifaceted approach to treating TED, tailored to the severity of each case. Her treatment regimen includes:

Medications: Utilizing corticosteroids and immunosuppressants to manage inflammation and other symptoms.

Innovative Surgical Techniques: For severe TED cases, Dr. Surbhi Kapadia offers surgical options such as orbital decompression, which alleviates pressure on the eye, and eyelid surgery to correct vision-related issues and improve cosmetic appearance.

Living with Thyroid Eye Disease: Insights and Tips

Living with TED involves continuous management. Dr. Kapadia advises:

Regular Monitoring: Keeping track of symptom progression and adjusting treatment plans accordingly.

Lifestyle Modifications: Implementing lifestyle changes like quitting smoking, which is known to exacerbate TED.

Eye Protection: Using sunglasses to protect the eyes from UV rays and environmental irritants.

Frequently Asked Questions About Thyroid Eye Disease Answered

Dr. Kapadia addresses common queries regarding TED, offering clear and concise information:

Diagnosis: Explaining the methods used to diagnose TED, including clinical assessments and imaging techniques.

Treatment Effectiveness: Discussing the success rates of different treatment options and what patients can expect.

Post-Treatment Care: Highlighting the importance of follow-up care post-treatment to ensure the best outcomes.

Conclusion:

Dr. Surbhi Kapadia's expertise in treating Thyroid Eye Disease makes her one of the best ophthalmologists in Vadodara for patients seeking specialized eye care. Her dedication to her patient's well-being ensures that they receive not only the best medical treatment but also the support and guidance needed to navigate through the complexities of TED.

[harmeet-saggi]

Juvenile Rheumatoid Arthritis

Juvenile rheumatoid arthritis (JRA), also known as juvenile idiopathic arthritis (JIA), is a form of arthritis that affects children. JRA causes inflammation and pain in one or more joints. The cause of JRA is unknown, but it may be the result of an immune system response gone wrong. It is not contagious.

[drpedi07]

Clobetasone Drug

Medical information for Clobetasone on Pediatric Oncall including Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Interaction, Hepatic Dose.

[healthcaretechnologynews]

Unraveling the Mystery: Diagnosis and Treatment of aTTP - Conquering a Rare Blood Disorder

In the vast world of medical conditions, some rare and lesser-known disorders can significantly impact the lives of those affected. One such condition is acquired Thrombotic Thrombocytopenic Purpura, commonly known as aTTP. This rare blood disorder is characterized by the formation of blood clots in small blood vessels throughout the body, leading to a low platelet count and potential organ damage. Despite its rarity, aTTP demands urgent attention and specialized care. This blog explores the diagnosis and treatment approaches for this challenging and potentially life-threatening condition.

Write to us at enquire@grgonline.com Learn how GRG Health is helping clients gather more in-depth market-level information on such topics.

Understanding aTTP

Thrombotic Thrombocytopenic Purpura (TTP) is a group of disorders, with aTTP being an acquired form of the disease. It primarily affects the microvasculature, leading to clot formation within small blood vessels, especially in the brain, heart, kidneys, and other vital organs. The formation of these clots can obstruct blood flow and cause damage to the affected tissues.

The exact cause of aTTP is not always clear. Still, it often involves an autoimmune response, where the body's immune system mistakenly targets and damages its own blood vessels and platelets. Certain triggers, such as infections, medications, or pregnancy, can potentially set off the disease in predisposed individuals.

Diagnosis of aTTP

Diagnosing aTTP can be challenging due to its rarity and similarity in symptoms with other conditions. A prompt and accurate diagnosis is crucial to initiate appropriate treatment promptly.

Healthcare providers may consider the following steps in diagnosing aTTP:

Clinical Assessment: The initial step involves a comprehensive review of the patient's medical history, including any recent infections or potential triggers, and a thorough physical examination.

Blood Tests: Blood tests are critical in diagnosing aTTP. The analysis may include a complete blood count to check for a low platelet count and a peripheral blood smear to look for abnormal red blood cells and platelet clumps.

ADAMTS13 Activity Test: This specialized test measures the activity of ADAMTS13, a specific enzyme responsible for breaking down large von Willebrand factor multimers in the blood. Reduced activity of ADAMTS13 is a hallmark feature of aTTP.

Other Tests: Additional tests, such as kidney and liver function tests, coagulation profiles, and assessment of organ damage, may be performed to evaluate the severity of the disease and its impact on vital organs.

Treatment of aTTP:

Treating aTTP requires a multidisciplinary approach involving hematologists, nephrologists, and other specialists. The main goals of treatment include stopping the formation of blood clots, increasing platelet count, and preserving organ function.

Depending on the severity of the disease, the following treatments may be employed:

Plasma Exchange (PE): PE is considered the first-line treatment for aTTP. During this procedure, the patient's plasma containing faulty antibodies and other pro-clotting factors is removed and replaced with fresh frozen plasma or other plasma products. This helps to remove the pathogenic components and restore the balance of clotting factors.

Corticosteroids: Corticosteroids, such as prednisone, are often used in combination with PE to suppress the immune response and reduce the production of autoantibodies that attack ADAMTS13.

Rituximab: In cases where PE and corticosteroids are insufficient, the monoclonal antibody rituximab may be used to target and deplete specific immune cells involved in the autoimmune response.

Immunosuppressants: Drugs such as cyclosporine or azathioprine can dampen the immune system and prevent further attacks on ADAMTS13.

Splenectomy: In some refractory cases, surgical removal of the spleen (splenectomy) may be considered to reduce the destruction of platelets and enhance treatment efficacy.

Supportive Care: Patients with aTTP often require supportive care, including close monitoring, pain management, and treatment for any associated organ damage.

Conclusion:

aTTP is a rare but serious blood disorder that demands timely diagnosis and appropriate treatment. The collaboration between medical professionals, advanced diagnostic tools, and novel therapies plays a vital role in improving outcomes for those affected by this condition. While aTTP presents significant challenges, ongoing research, and medical advancements offer hope for better management and potentially a cure in the future. Early recognition, proper intervention, and continuous support are essential in the journey towards bettering the lives of individuals battling this rare blood disorder.

Visit our website now: https://www.grgonline.com/

[regenhealthsolutions]

Study reveals novel action mechanism of corticosteroids in combating inflammation caused by COVID-19

Study reveals novel action mechanism of corticosteroids in combating inflammation caused by #COVID-19

Since the start of the COVID-19 pandemic, a class of corticosteroids called glucocorticoids (GCs) have become established as one of the main treatment options, especially for severe cases, thanks to their anti-inflammatory and immunosuppressant action. Brazilian researchers recently discovered new ways in which these drugs influence the organism��s inflammatory response during an infection: they…

[healthiswe]

Understanding and Managing Asthma

[creativeera]

The Duchenne Muscular Dystrophy Treatment Market is Trending Towards Gene Therapy

The Duchenne Muscular Dystrophy Treatment market is experiencing promising trends through gene therapy. Duchenne muscular dystrophy (DMD) is a rare genetic disorder characterized by progressive muscle degeneration and weakness. The condition is caused due to the lack of dystrophin protein which helps keep muscle cells intact. The standard of care currently involves corticosteroids to delay the progression. However, gene therapy is emerging as a breakthrough in finding a cure. The Duchenne muscular dystrophy treatment market comprises products for replacing the missing dystrophin gene or gene therapy. Exon skipping medications and gene therapies aim to restore functional dystrophin production. These advanced treatments address the underlying cause of DMD by repairing the genetic mutation. The gene therapy products offer hope of a one-time administration with long-lasting effects against this currently incurable disease. The global Duchenne muscular dystrophy treatment market is estimated to be valued at US$ 1.5 billion in 2024 and is expected to exhibit a CAGR of 47% over the forecast period 2024-2034.

Growing research activities towards finding a cure and rising investment in novel therapeutics are fueling the market growth. Key Takeaways Key players operating in the Duchenne muscular dystrophy treatment market are Sarepta Therapeutics, Pfizer, PTC Therapeutics, Solid Biosciences etc. Sarepta Therapeutics dominates with its exon skipping drug Exondys 51 as the first approved medication. The Duchenne Muscular Dystrophy Treatment Market Trend is growing significantly owing rising diagnosis rates and growing medical needs of the patient population. According to Parent Project Muscular Dystrophy, around 1 in every 3,500 male children is born with DMD. Growing patient advocacy is also driving awareness and screening. The market is witnessing expansion into new geographical regions with ongoing clinical trials of gene therapies. Players are evaluating therapies across regions like Europe, Asia, and other developed markets. Positive data is also attracting strategic collaborations and investments towards commercialization. Market Key Trends One of the major trends in the Duchenne Muscular Dystrophy treatment market is the promising pipeline of gene therapies. Several gene therapies are in late stage development addressing critical unmet needs. Select candidates have shown efficacy in animal studies and early human trials. Pfizer's gene therapy candidate is anticipated to be a blockbuster on approval. Its widespread adoption could potentially capture a sizable market share, driving the gene therapy trend further.

Porter's Analysis Threat of new entrants: High barrier to entry due to expensive R&D and clinical trials required.

Bargaining power of buyers: Limited bargaining power of patients suffering from rare disease.

Bargaining power of suppliers: Strong bargaining power of suppliers due to limited treatment options.

Threat of new substitutes: Low threat due to no effective treatment substitutes currently available.

Competitive rivalry: High competitive rivalry among existing players to develop innovative treatments. Geographical Regions North America region holds the major share of the global Duchenne muscular dystrophy treatment market in terms of value, owing to higher adoption of high-priced therapies. The U.S. accounts for the largest share of the North America as well as global market. Asia Pacific region is expected to witness the fastest growth during the forecast period majorly driven by increasing healthcare expenditure, large patient pool and rising awareness about treatment options in emerging countries such as China and India.

Get more insights on Duchenne Muscular Dystrophy Treatment Market

Discover the Report for More Insights, Tailored to Your Language

French

German

Italian

Russian

Japanese

Chinese

Korean

Portuguese

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)

[noxious-fennec]

A redraw of an old thing because exam season is the only time i get creative energy ig